Press Releases

Our latest news and press releases

Calyxt, Inc., Cellectis’ Majority-Owned Subsidiary, Reports Its First Quarter 2022 Financial Results

Read more

Cellectis Publishes Two Articles in Nature Communications Providing Strong Preclinical Validation of UCART123 to Treat AML and BPDCN

Read more

Cellectis Receives $20 Million Convertible Note Under Collaboration Agreement with its Partner Cytovia Therapeutics

Read more

Cellectis Presents Preclinical Data from its First Allogeneic Dual CAR T-cell Product Candidate UCART20x22 for Patients with Relapsed or Refractory Non-Hodgkin Lymphoma at the American Association for Cancer Research (AACR) 2022 Annual Meeting

Read more

Cellectis to Participate in Two Upcoming Investor Conferences in March

Read more

Cellectis Provides Business Update and Reports 4th Quarter and Full Year 2021 Financial Results

Read more

Cellectis to Hold Fourth Quarter 2021 Earnings Call on Friday March 4, 2022 at 8:00AM EST

Read more

Calyxt Announces Pricing of Offering of Common Stock and Warrants and Updates Business and Risk Factor Disclosure

Read more

Cellectis Appoints Bing Wang, PhD, MBA as Chief Financial Officer

Read more

Cellectis’ Licensed Partner, Allogene Therapeutics,  Announces Removal of FDA Clinical Hold on their Clinical Trials

Read more